Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase EARLY_PHASE1 1Phase 1/2 1

Status

Recruiting 2Terminated 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2

Conditions

Lymphoma, Mantle-Cell 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Hairy Cell 1

Interventions

Specimen Handling 276pembrolizumab 227Magnetic Resonance Spectroscopy 226Carboplatin 180Cisplatin 166Biopsy 166Nivolumab 158Cyclophosphamide 144Radiotherapy 125Paclitaxel 124Gemcitabine 116Bevacizumab 95durvalumab 92Dexamethasone 88Rituximab 81Oxaliplatin 80venetoclax 75atezolizumab 71Fluorouracil 70Docetaxel 70Capecitabine 70Doxorubicin 68Etoposide 65Radiosurgery 64Ipilimumab 63Radiation 61Prednisone 60Cytarabine 60Lenalidomide 58Pemetrexed 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × brexucabtagene autoleucel × 90 days × Clear all
NCT06144606 2026-03-31

Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL)

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06553872 2026-03-31

Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
60 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT02601313 2026-03-18

ZUMA-2

Gilead Sciences

Phase 2 Completed
105 enrolled 33 charts 1 FDA
Lymphoid

Lymphoma, Mantle-Cell

NCT05537766 2026-03-10

ZUMA-25

Gilead Sciences

Phase 2 Terminated
19 enrolled 28 charts
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Hairy Cell, Waldenstrom Macroglobulinemia, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡